This Executive Overview outlines the proof-of-concept study completed by Predictive Oncology to illustrate the power of our active machine learning (AI) platform paired with our biobank of over 150,000 primary patient dissociated tumor samples. The described validation results demonstrate the generation of a predictive model that was able to accurately predict drug response across 130 samples and 175 drugs.

White Paper
Abandoned oncology drugs -Identifying new indications using active machine learning and a biobank of patient derived dissociated tumor cells (DTCs)
Drug repurposing using the Predictive Oncology machine learning approach and proprietary biobank of frozen dissociated tumor cells (DTCs) is outlined in this new white paper.